Senior healthcare executive Lutz J. Voelker has been appointed as CEO of inventicsDx,
a leading digital diagnostics plattform provider for rapid molecular testing
Berlin,Germany, July 09, 2021
“We cordialy welcome Lutz as our new CEO. We are gaining a very experienced healthcare & lifescience senior executive who has already given us decisive impetus for our DNA and platform product strategy. With him we will successfully implement our growth strategy in key markets “Pathogen Monitoring” and “Human DNA Diagnostics”, says Dr. Albrecht Bochow (Chairman of GPS venture).
Lutz is an accomplished senior executive with 30+ years of executive management experience and strong entrepreneurial, international business development and corporate transaction background. He is a specialist in big data in life-sciences and healthcare, platform-oriented businesses, digital transformation and its related economic impacts to sustainable growth. Previously he served as CEO at Molecular Health, Inc. Boston, USA and Heidelberg, Germany, a NGS based diagnostics and Bioinformatics company in the area of cancer diagnostics. Prior to that he served as CEO of a technology investment arm of a large Swiss family office consortium, Global Head of SAP’s healthcare division and EMEA Product Line Manager for Lab Automation and LIMS at Agilent Technologies. Lutz is founder of aspect.partners, an international industry advisory practice in the technology and life sciences sector that advises healthcare and technology-oriented investors. He holds a master degree in Biomedical Engineering from THM Technical University of Giessen, Germany.
“By launching the first microfluidic-based digital rapid testing system for the detection of Legionella in drinking water, we are opening a new chapter in digital diagnostics and analysis of pathogens. Fast reliable results, digitally processed and made available in the cloud will support quick decisions in mission critical situations. This is what todays technology can provide and what our customers, physicians and patients expect from us.
Additionally, we are close to market maturity of our novel microfluidic-based DNA sensor technolgy, which opens up another very large clinical application potential in routine diagnostics, but also in clinical research and pharma. Our mission is: “One platform, multiple targets – bacteria, viruses, human DNA, other DNA. Our goal is to become one of the leading providers in the field of rapid molecular diagnostics,” Lutz said.